Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Milestone to market Access’s MuGard product in US and Canada
Under the terms of the agreement, Milestone will pay Access upfront license fees and subsequent milestone payments that total $10 million along with a double digit royalty upon
Under the terms of the agreement, Milestone will pay Access upfront license fees and subsequent milestone payments that total $10 million along with a double digit royalty upon
Terms of the sale include an upfront payment of $1 million in cash paid at closing to Forbes along with potential future payments of up to $6 million,
Paul Reid, CEO of ReceptoPharm, said: “Initial reports and feedback from physicians involved with this clinical study have reported that patients have experienced no adverse side effects from
The single-center, Phase Ib trial examined the safety, tolerability and pharmacokinetics of intravenous bolus plus infusion dosing of NU172, in 24 healthy male volunteers. Volunteers were given a
EquivaBone is a proprietary combination of osteoinductive demineralized bone matrix (DBM) and Etex’s osteoconductive nanocrystalline calcium phosphate. EquivaBone is intended for use in filling bone voids or defects
Dr Stein currently serves on the president’s board of advisors for science and innovation for the University of California and is scientific advisor to Takeda San Diego. David
Dr Philip succeeds Richard Sessions, Znomics co-founder and interim CEO, who will remain as a consultant to the company and as an active member of Znomics’s board of
The agreement includes $257 million in potential payments to GTC for meeting clinical, regulatory, and sales milestones, including a $3 million payment from Ovation to GTC at the
Ranexa is approved for use in Europe as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to
Dr Parry-Billings joined Topigen in 2007 as chief development officer and expanded his role to lead the company’s operations in early 2008. Previously, Dr Parry-Billings was European director